Karessa starts collaboration with Pharma Consulting Group for upcoming pivotal clinical programmme
Karessa has entered into a cooperation agreement with the contract research company Pharma Consulting Group. The agreement gives Karessa access to a well-reputed partner in the ongoing work to develop next-generation pharmaceuticals to treat erectile dysfunction.
Karessa is currently working with two projects in the therapeutic area of erectile dysfunction. Both projects are in pre-clinical phase and consists of Karessa's unique and patented drug delivery platform in combination with Sildenafil and Tadalafil, the active substances in tablet form of Viagra and Cialis.
The concluded agreement means that PCG will assist in the work on planning, implementation and registration of Karessa's drug candidate based on the drug delivery platform in combination with the active substance Sildenafil.
"The work that we are now planning together with PCG are important milestones in the ongoing development work. Pharma Consulting Group matches our needs very well. With this collaboration, we get a competent partner with extensive experience in drug development and the regulations. With a presence in Sweden, China, India and Japan, PCG also has the capacity to assist us in a global market" says Torbjörn Kemper, CEO at Karessa in a comment.
"We look forward to working with a new, innovative Swedish company. Karessa's drug delivery film involves a new drug delivery method that is very exciting. We believe and hope that our expertise, experience and processes will be of great value" says Andy Babington, CEO at Pharma Consulting Group.
Quick and reliable onset
Karessa's pharmaceuticals will not be administered in tablet form, instead it will be delivered directly into the bloodstream via the oral mucosa via a buccal film. By this way a faster and significantly more reliable effect than today's tablet options.
A multi-billion market
Erectile dysfunction, i.e. an inability to achieve and maintain erection successfully to perform sexual activity affects nearly half of all men over 40 years. The global market is currently valued to approximately $ 4.3 billion.
For more information, please visit karessa.se – or contact:
Torbjörn Kemper
CEO
+46(0) 76 111 39 80
torbjorn.kemper@karessa.se
About Karessa Pharma Holding AB
Karessa Pharma Holding AB develops and commercializes next-generation pharmaceuticals to treat erectile dysfunction. Karessa's concept is based on a patented drug delivery film, which is combined with clinically tested and well proven active substances. The combination enables pharmaceuticals with both a direct and reliable effect. Karessa is listed on Nasdaq First North. www.karessa.se
Tags: